Objective This review aimed to assess the efficacy and safety of GnRH antagonists in
patients with symptomatic uterine fibroids. Data Sources A literature search was performed …

Novel gonadotrophin releasing hormone (GnRH) antagonist treatments have recently been
developed in combination with hormonal add‐back therapy, as an oral treatment option for …

Objective To evaluate the efficacy and safety of 24 weeks of treatment with the oral GnRH
receptor antagonist, relugolix, in combination with estradiol (E2) and norethindrone acetate …

Background Uterine fibroids (also known as leiomyomas) are the most common benign
pelvic tumours among women. They may be asymptomatic, or may be associated with pelvic …

Introduction Uterine fibroids (UF) are benign tumors common in premenopausal women,
with strong impact on the health-care systems. For many years, surgery represented the only …

Introduction Uterine fibroids are the most common noncancerous tumors in women of
childbearing age. This review was developed to evaluate the current role of gonadotropin …

Use of oral GnRH antagonists combined therapy in the management of symptomatic uterine
fibroids - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

Uterine fibroids (UFs) are the most common gynaecological benign disease. Even though
often asymptomatic, UFs can worsen women's health and their quality of life, causing heavy …

Introduction Uterine fibroids, the most prevalent benign tumors among reproductive-age
women, pose treatment challenges that range from surgical interventions to medical …

ABSTRACT Introduction: Uterine fibroids (UFs) are the most prevalent benign neoplastic
threat originating from myometria of reproductive age women, with a profound financial load …